For an individual confirmed to carry a BRCA2 mutation, a structured, lifelong surveillance plan should be established in coordination with a clinical geneticist, oncologist, and gynaecologist, since the elevated risk applies to multiple organ systems and not breast tissue alone.

*For breast cancer surveillance, clinical breast examination should be performed every six to twelve months starting at age twenty-five, alongside annual breast magnetic resonance imaging beginning at age twenty-five, with annual mammography added from age thirty onward, and both imaging modalities are typically alternated every six months so that the breast tissue is monitored twice a year in total. Breast self-awareness training should also be provided so that any new lump, skin change, or nipple discharge is reported promptly rather than waiting for the next scheduled screening.
*For ovarian cancer, routine screening using transvaginal ultrasound and the blood marker cancer antigen 125 has not been shown to reliably detect ovarian cancer at an early stage, so the primary proactive step recommended is risk-reducing bilateral salpingo-oophorectomy between the ages of forty and forty-five or after childbearing is complete, since no effective early detection tool currently exists for this cancer type. Because BRCA2 mutations also raise the lifetime risk of pancreatic cancer, individuals with a family history of pancreatic cancer should discuss annual surveillance using magnetic resonance imaging or endoscopic ultrasound with a specialist, typically starting around age fifty or ten years before the earliest pancreatic cancer diagnosis in the family.
*Men who carry a BRCA2 mutation should begin prostate-specific antigen based prostate cancer screening earlier than the general population, generally from the age of forty years, given the documented increase in prostate cancer risk and aggressiveness associated with this gene.
*Skin examinations for melanoma should also be discussed with a dermatologist given the associated risk. Alongside clinical surveillance, lifestyle measures that support overall risk reduction include maintaining a healthy body weight, limiting alcohol consumption, avoiding tobacco use, and staying physically active, since these factors influence overall cancer risk even though they do not eliminate the genetic risk itself.

Finally, genetic counseling should be revisited periodically, since surveillance guidelines are updated as research evolves, and family planning discussions, including options such as preimplantation genetic testing, should be raised with a fertility specialist if the individual is considering having children.